Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Medincell SA has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The presence of only 1 pending office action indicates a very focused current prosecution profile. This single pending action represents the total active workload for the company at this time.
LEESER, ERICH A is the busiest examiner for the company, managing 1 pending office action. This individual is the sole distinct examiner for the company's current pending matters. The concentration in 1 distinct art unit suggests that the company's biotechnology innovation is being reviewed within a single specialized technical group. This structure allows for a very direct line of communication between the applicant and the patent office for its 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEESER, ERICH A | 1 | 81.9% | +13.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18409158 | OLANZAPINE COMPOSITIONS AND METHODS OF USE | LEESER, ERICH A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18409158 | OLANZAPINE COMPOSITIONS AND METHODS OF USE | LEESER, ERICH A | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18409158 | OLANZAPINE COMPOSITIONS AND METHODS OF USE | LEESER, ERICH A | 1622 | §101 | Non-Final OA | — | Pending | Jan 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedincell SA has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Erich A Leeser has the most, with 1 of Medincell SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
